Durable Response to Dabrafenib Combined With Trametinib in a Patient With NSCLC Harboring a BRAF G469A Mutation

J Thorac Oncol. 2020 Oct;15(10):e174-e176. doi: 10.1016/j.jtho.2020.07.007.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Humans
  • Imidazoles
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Mutation
  • Oximes
  • Proto-Oncogene Proteins B-raf* / genetics
  • Pyridones / therapeutic use
  • Pyrimidinones

Substances

  • Imidazoles
  • Oximes
  • Pyridones
  • Pyrimidinones
  • trametinib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • dabrafenib